Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487216 | 0.85 | CYP3A4 (0.72) | CYP3A4ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL2487340 | 0.85 | CYP3A4 (0.53) | CYP3A4ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL6832548 | 0.80 | CYP3A4 (0.38) | CYP3A4CYP19A1 | |
| SCHEMBL10134577 | 0.78 | CYP3A4 (0.51) | CYP3A4ADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL6832516 | 0.76 | ITK (0.43) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1543003 | 0.76 | CYP3A4 (0.53) | CYP3A4CYP19A1DHFR | |
| SCHEMBL1542227 | 0.75 | CYP3A4 (0.47) | CYP3A4CYP19A1DHFR | |
| SCHEMBL1543205 | 0.72 | CYP3A4 (0.74) | CYP3A4ADORA2AADORA1 | |
| SCHEMBL1542866 | 0.72 | CYP3A4 (0.73) | CYP3A4 | |
| SCHEMBL6832550 | 0.72 | GPR84 (0.34) | CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CYP3A4 978/4885ADRA2A 1156/4885ADRA2C 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.